Sarepta Therapeutics, Inc. (SRPT) Strategic Restructure and ELEVIDYS Label Update Call TranscriptSeeking Alpha • 07/18/25
Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source saysReuters • 07/18/25
Sarepta Therapeutics Crashes After A Third Gene Therapy Patient DiesInvestors Business Daily • 07/18/25
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) ShareholdersPRNewsWire • 07/18/25
SRPT INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitPRNewsWire • 07/18/25
SRPT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitGlobeNewsWire • 07/17/25
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPTGlobeNewsWire • 07/17/25
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline PivotsZacks Investment Research • 07/17/25
The Gross Law Firm Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPTPRNewsWire • 07/17/25
Sarepta To Lay Off 500 Employees After Two Patient Deaths; Shares CatapultInvestors Business Daily • 07/17/25
Kessler Topaz Meltzer & Check, LLP Notifies Sarepta Therapeutics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action LawsuitGlobeNewsWire • 07/16/25
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS LabelBusiness Wire • 07/16/25
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsGlobeNewsWire • 07/16/25